Detalhe da pesquisa
1.
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
N Engl J Med
; 387(12): 1099-1110, 2022 09 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36129998
2.
Amyotrophic lateral sclerosis: update on clinical management.
Curr Opin Neurol
; 33(5): 641-648, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32868602
3.
Amyotrophic lateral sclerosis care and research in the United States during the COVID-19 pandemic: Challenges and opportunities.
Muscle Nerve
; 62(2): 182-186, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32445195
4.
CK-2127107 amplifies skeletal muscle response to nerve activation in humans.
Muscle Nerve
; 57(5): 729-734, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29150952
5.
The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis.
Brain
; 145(4): 1207-1210, 2022 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35020823
6.
MiToS and King's staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial.
Amyotroph Lateral Scler Frontotemporal Degener
; 24(3-4): 304-310, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36503310
7.
Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS.
J Med Econ
; 26(1): 488-493, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36930042
8.
Randomized double-blind personalized N-of-1 clinical trial to test the safety and potential efficacy of TJ-68 for treating muscle cramps in amyotrophic lateral sclerosis (ALS): study protocol for a TJ-68 trial.
Trials
; 24(1): 449, 2023 Jul 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37430314
9.
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success.
Amyotroph Lateral Scler Frontotemporal Degener
; 24(5-6): 523-534, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37254449
10.
Medical therapies for amyotrophic lateral sclerosis-related respiratory decline: an appraisal of needs, opportunities and obstacles.
Amyotroph Lateral Scler Frontotemporal Degener
; 23(1-2): 66-75, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34392765
11.
Amyotrophic Lateral Sclerosis Clinical Trials and Interpretation of Functional End Points and Fluid Biomarkers: A Review.
JAMA Neurol
; 79(12): 1312-1318, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36251310
12.
Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of reldesemtiv in ALS: post hoc analyses of a randomized, double-blind, placebo-controlled clinical trial.
Amyotroph Lateral Scler Frontotemporal Degener
; 23(3-4): 263-270, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34218726
13.
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.
Neurotherapeutics
; 19(4): 1248-1258, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35585374
14.
Noninvasive ventilation use by patients enrolled in VITALITY-ALS.
Amyotroph Lateral Scler Frontotemporal Degener
; 22(7-8): 486-494, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33792451
15.
Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study.
Neurotherapeutics
; 18(2): 1127-1136, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33624184
16.
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS.
Amyotroph Lateral Scler Frontotemporal Degener
; 22(3-4): 287-299, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32969758
17.
Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis.
Amyotroph Lateral Scler Frontotemporal Degener
; 21(7-8): 509-518, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32573277
18.
Clinical neurophysiology of anterior horn cell disorders.
Handb Clin Neurol
; 161: 317-326, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31307610
19.
ALS drug development guidances and trial guidelines: Consensus and opportunities for alignment.
Neurology
; 93(2): 66-71, 2019 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31171646
20.
A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis.
Amyotroph Lateral Scler Frontotemporal Degener
; 0(0): 1-11, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31081694